TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases. The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and Treg function to identify and characterize therapeutic targets, using Computational Mapping, which uses in silico tools and a human tissue bank and atlas of human Treg gene expression to identify pathways in tissue immune regulation; the Treg Atlas, which recreates tissue states in Tregs and reprograms blood-derived Tregs to recreate human tissue-specific pathways in vitro for target validation; and the Phenotypic Assay Cascade, a suite of high-throughput functional fingerprinting assays that test targets across donors and inflammatory contexts. The company develops TRB-061 an investigational tumor necrosis factor receptor 2 (TNFR2) agonist and fragment crystallizable-fusion (Fc-fusion) protein designed to selectively agonize TNFR2 to activate and expand Tregs in inflamed tissues. The company also develops TRB-071, an agonist designed to augment tissue Tregs and block an inflammatory signaling pathway, for inflammatory bowel disease. Additionally, it advances TRB-051, a partnered modulator of immune effector cells, for autoimmune and inflammatory diseases including lupus with cutaneous involvement. The company also advances preclinical-stage programs addressing tissue Treg biology informed by the Deep Biology Platform. TRex Bio, Inc. was incorporated in 2018 and is based in South San Francisco, California. more
| Dec '24 | Dec '25 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | 39.11M | - | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Cost of Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Profit | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Margin | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Operating Expenses | 41.49M | 37.84M | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":91.22,"profit":true}] | |||
| Operating Income | (2.38M) | (37.84M) | [{"date":"2024-12-31","value":-238100000,"profit":false},{"date":"2025-12-31","value":-3784500000,"profit":false}] | |||
| Total Non-Operating Income/Expense | 1.94M | 3.08M | [{"date":"2024-12-31","value":62.79,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Pre-Tax Income | (444.00K) | (34.76M) | [{"date":"2024-12-31","value":-44400000,"profit":false},{"date":"2025-12-31","value":-3476000000,"profit":false}] | |||
| Income Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income After Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income From Continuous Operations | (3.14M) | (34.81M) | [{"date":"2024-12-31","value":-314400000,"profit":false},{"date":"2025-12-31","value":-3480600000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Net Income | (3.14M) | (34.81M) | [{"date":"2024-12-31","value":-314400000,"profit":false},{"date":"2025-12-31","value":-3480600000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| TRXB | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| TRXB | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
TRex Bio, Inc. Common stock (TRXB) share price today is $13.79
Yes, Indians can buy shares of TRex Bio, Inc. Common stock (TRXB) on Vested. To buy
Yes, you can purchase fractional shares of TRex Bio, Inc. Common stock (TRXB) via the Vested app. You can start investing in TRex Bio, Inc. Common stock (TRXB) with a minimum investment of $1.
You can invest in shares of TRex Bio, Inc. Common stock (TRXB) via Vested in three simple steps:
The 52-week high price of TRex Bio, Inc. Common stock (TRXB) is $16.56. The 52-week low price of TRex Bio, Inc. Common stock (TRXB) is $13.21.
The price-to-earnings (P/E) ratio of TRex Bio, Inc. Common stock (TRXB) is
The price-to-book (P/B) ratio of TRex Bio, Inc. Common stock (TRXB) is 0.00
The dividend yield of TRex Bio, Inc. Common stock (TRXB) is 0.00%
The market capitalization of TRex Bio, Inc. Common stock (TRXB) is $396.04M
The stock symbol (or ticker) of TRex Bio, Inc. Common stock is TRXB
Consider the share price of TRex Bio, Inc. Common stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether TRex Bio, Inc. Common stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in TRex Bio, Inc. Common stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the TRex Bio, Inc. Common stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of TRex Bio, Inc. Common stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that TRex Bio, Inc. Common stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied
